ENHABIT INC

Company Overview

Enhabit Inc. (EHAB) is a U.S. provider of Medicare‑certified home health and hospice services, operating 255 home health agencies and 115 hospice locations across dozens of states and serving roughly 41,000 home health and 3,500 hospice patients daily (2024). The business is highly Medicare‑concentrated (≈90% Medicare/Medicare Advantage revenue), with Home Health representing ~80% of services revenue and Hospice ~20%, and competes on market density, clinical outcomes, and technology-enabled productivity. Key operating levers are referral flows from post‑acute facilities and physicians, Medicare/MA reimbursement rules, branch-level scale, targeted de novo expansion and selective acquisitions, while material risks include CMS payment changes, audits/False Claims Act exposure, labor inflation and goodwill/impairment sensitivity.

Executive Compensation Practices

Given management disclosures, executive pay at Enhabit is likely structured around a mix of base salary, annual cash incentives and long‑term equity where performance measures emphasize Adjusted EBITDA, operating cash flow, segment census/revenue per patient day and successful M&A/market density outcomes. Quality and compliance metrics (HHCAHPS/Quality of Patient Care scores, readmission/hospitalization rates, and audit/compliance outcomes) are material non‑financial drivers that likely factor into incentives because they directly affect reimbursement and payer relationships. The 2024 goodwill impairment, recurring litigation/audit exposure and the company’s reliance on CMS rules make contingent/ex post risk adjustments, clawback provisions and performance‑vesting equity typical; retention awards and change‑in‑control/separation provisions are also probable given recent separations and restructuring.

Insider Trading Considerations

Insiders' trading patterns at Enhabit are likely to cluster around discrete, material events: CMS proposed/final rule announcements (particularly the proposed Home Health rate cut), quarterly earnings releases showing Adjusted EBITDA/cash flow trends, large impairment or reserve disclosures, and M&A or branch expansion announcements. Because so much of value depends on reimbursement policy and audit outcomes, non‑public information about CMS reviews, Medicare Advantage contract wins/losses, or significant claim audit results would be highly material — expect use of 10b5‑1 plans and customary blackout windows; Section 16 reporting (Form 4) activity will therefore be important to monitor. Finally, insiders may trade in patterns tied to covenant or liquidity milestones (e.g., exit of covenant adjustment periods or revolver availability) and any observed trades immediately before or after major regulatory or audit disclosures warrant heightened scrutiny.